HomeCompareTCPC vs LLY

TCPC vs LLY: Dividend Comparison 2026

TCPC yields 28.25% · LLY yields 0.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LLY wins by $1.49M in total portfolio value· pulled ahead in Year 7
10 years
TCPC
TCPC
● Live price
28.25%
Share price
$3.54
Annual div
$1.00
5Y div CAGR
-15.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.0K
Annual income
$1,317.64
Full TCPC calculator →
LLY
LLY
● Live price
0.70%
Share price
$886.67
Annual div
$6.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.54M
Annual income
$1,207,534.19
Full LLY calculator →

Portfolio growth — TCPC vs LLY

📍 LLY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCPCLLY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCPC + LLY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCPC pays
LLY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCPC
Annual income on $10K today (after 15% tax)
$2,401.13/yr
After 10yr DRIP, annual income (after tax)
$1,119.99/yr
LLY
Annual income on $10K today (after 15% tax)
$59.72/yr
After 10yr DRIP, annual income (after tax)
$1,026,404.06/yr
At 15% tax rate, LLY beats the other by $1,025,284.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCPC + LLY for your $10,000?

TCPC: 50%LLY: 50%
100% LLY50/50100% TCPC
Portfolio after 10yr
$793.4K
Annual income
$604,425.92/yr
Blended yield
76.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on LLY right now

TCPC
Analyst Ratings
4
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$8.00
+126.0% upside vs current
Range: $8.00 — $8.00
Altman Z
-1.0
Piotroski
6/9
LLY
Analyst Ratings
33
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$1,243.95
+40.3% upside vs current
Range: $985.00 — $1,350.00
Altman Z
7.7
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCPC buys
0
LLY buys
0
No recent congressional trades found for TCPC or LLY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCPCLLY
Forward yield28.25%0.70%
Annual dividend / share$1.00$6.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-15.2%100%
Portfolio after 10y$49.0K$1.54M
Annual income after 10y$1,317.64$1,207,534.19
Total dividends collected$20.5K$1.49M
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusHoldBuy
Analyst price target$8.00$1,243.95

Year-by-year: TCPC vs LLY ($10,000, DRIP)

YearTCPC PortfolioTCPC Income/yrLLY PortfolioLLY Income/yrGap
1$13,095$2,395.48$10,841$140.53+$2.3KTCPC
2$16,498$2,486.14$11,884$284.74+$4.6KTCPC
3$20,135$2,482.31$13,299$583.47+$6.8KTCPC
4$23,946$2,400.99$15,451$1,220.47+$8.5KTCPC
5$27,885$2,262.94$19,183$2,650.30+$8.7KTCPC
6$31,926$2,088.46$26,676$6,150.32+$5.3KTCPC
7← crossover$36,055$1,894.98$44,530$15,986.45$8.5KLLY
8$40,275$1,696.08$97,527$49,880.25$57.3KLLY
9$44,596$1,501.51$308,551$204,197.51$264.0KLLY
10$49,035$1,317.64$1,537,684$1,207,534.19$1.49MLLY

TCPC vs LLY: Complete Analysis 2026

TCPCBDC

BlackRock TCP Capital Corp. is a business development company specializing in direct equity and debt investments in middle-market, debt securities, senior secured loans, junior loans, originated loans, mezzanine, senior debt instruments, bonds, and secondary-market investments. It typically invests in communication services, public relations services, television, wireless telecommunication services, apparel, textile mills, restaurants, retailing, energy, oil and gas extraction, Patent owners and Lessors, Federal and Federally- Sponsored Credit agencies, insurance, hospital and healthcare centers, Biotechnology, engineering services, heavy electrical equipment, tax accounting, scientific and related consulting services, charter freight air transportation, Information technology consulting, application hosting services, software diagram and design, computer aided design, communication equipment, electronics manufacturing equipment, computer components, chemicals. It seeks to invest in the United States. The fund typically invests between $10 million and $35 million in companies with enterprise values between $100 million and $1500 million including complex situations. It prefers to make equity investments in companies for an ownership stake.

Full TCPC Calculator →

LLYHealthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Full LLY Calculator →
📬

Get this TCPC vs LLY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCPC vs SCHDTCPC vs JEPITCPC vs OTCPC vs KOTCPC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.